Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing
NCT ID: NCT03271580
Last Updated: 2024-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
31 participants
OBSERVATIONAL
2020-02-01
2021-09-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence
NCT05172089
Mechanisms Underlying Impaired Diabetic Wound Healing
NCT00777712
Diabetic Foot Ulcers Microbiome and Pathogen Identification
NCT05556954
Diabetic Foot Ulcer Recurrence: Pilot Study
NCT03479242
Developing a Diabetic Foot Ulcer Protocol
NCT01068171
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Informed consent will be signed (if not previously signed)
* A hemoglobin A1c drawn will be taken by research personnel, if one has not been done within the last 90 days to check your average blood sugar level.
* An Ankle Brachial Index (ABI) will be obtained if the participant has a leg wound. This is to ensure that participants have adequate blood flow to your wound. This is a non-invasive test which measures blood pressure in both of the participants arms and ankles.
* Demographics (such as your name and address and phone number, age), medical history, current medications, current standard of care labs, and wound data (measurements, cause of the wound, wound culture, assessments, treatments, and duration) will be recorded. The participant's medical record number will also be recorded.
* A photo of the wound site will be taken.
* Wound Vac Collection - The wound vac sponge will be collected (waste by product of the therapy) by the research staff.
* An optional two 3 mm punch tissue biopsies will be obtained from the participant's provider. To perform the biopsy, the area surrounding the wound will first be numbed using a local anesthetic agent that will be injected at the wound site. Then, a pencil-like instrument will be used to remove a small, thin cylinder of tissue. Each biopsy is about the size of this dot. After the tissue is removed, a sterile gauze will be placed on the area to stop any minor bleeding that may occur. The biopsies will be looked at in the laboratory to look at the microorganisms. You will not receive the results of the completed laboratory analysis. (Note: If two biopsies cannot be obtained per your physician's discretion, only one biopsy, debridement tissue (dead tissue that is removed from your wound) or no tissue will be obtained, and/or culture swabs (your wound will be swabbed with something like a Q-tip to collect cells to test for bacteria or other organisms in the wound) will be collected to test for infection.)
During the 14-week follow-up visit, research staff will review the participant's medical chart to determine the final status of the wound. If the participant does not return to the CWC at 14 weeks, the last CWC visit will be documented as the wound check follow-up. This does not require the participant to return for an extra study visit. This information will only be collected from their medical chart if available:
* Final status of the wound (healing, not healing, healed)
* Wound data (measurements), treatments, and any standard of care labs will be obtained
* A photo of your wound from the medical chart will be obtained (if available)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diabetic patients infected ulcers
Diabetic patients with HbA1c\<9 with who have wound 4weeks or longer with infection with following interventions:
1. Finger prick test for HbA1c measurement
2. Punch biopsy
3. VAC sponge collection
4. Ankle brachial index
Finger prick test for HbA1c measurement
HbA1c measurement with finger prick method
Punch Biopsy
Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
Vac Sponge Collection
NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
Ankle Brachial Index
Blood pressure test
Diabetic patients non infected Ulcers
Diabetic patients with HbA1c\<9 who have wound 4 weeks or longer without infection with following interventions:
1. Finger prick test for HbA1c measurement
2. Punch biopsy
3. VAC sponge collection
4. Ankle brachial index
Finger prick test for HbA1c measurement
HbA1c measurement with finger prick method
Punch Biopsy
Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
Vac Sponge Collection
NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
Ankle Brachial Index
Blood pressure test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Finger prick test for HbA1c measurement
HbA1c measurement with finger prick method
Punch Biopsy
Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
Vac Sponge Collection
NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
Ankle Brachial Index
Blood pressure test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing and able to provide informed consent
3. Willing and able to comply with protocol instructions, including biopsies and study visits
4. Diabetics with an open wound
5. Receiving Negative Wound Pressure Therapy (NPWT)
Exclusion Criteria
1. TcOM \< 30mmHg
2. ABI \< 0.7
3. TBI \< 0.6
2. Women who are pregnant
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Sashwati Roy
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sashwati Roy, PhD
Role: PRINCIPAL_INVESTIGATOR
Indiana University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IU Health Methodist Hospital
Indianapolis, Indiana, United States
Davis Heart and Lung Institute
Columbus, Ohio, United States
The Ohio State University Hospital East
Columbus, Ohio, United States
Comprehensive Wound Care Centers, The Ohio State University Hospital
Columbus, Ohio, United States
Martha Morehouse Medical Plaza
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Breen JD, Karchmer AW. Staphylococcus aureus infections in diabetic patients. Infect Dis Clin North Am. 1995 Mar;9(1):11-24.
Davis SC, Martinez L, Kirsner R. The diabetic foot: the importance of biofilms and wound bed preparation. Curr Diab Rep. 2006 Dec;6(6):439-45. doi: 10.1007/s11892-006-0076-x.
James GA, Swogger E, Wolcott R, Pulcini Ed, Secor P, Sestrich J, Costerton JW, Stewart PS. Biofilms in chronic wounds. Wound Repair Regen. 2008 Jan-Feb;16(1):37-44. doi: 10.1111/j.1524-475X.2007.00321.x. Epub 2007 Dec 13.
Hanke ML, Angle A, Kielian T. MyD88-dependent signaling influences fibrosis and alternative macrophage activation during Staphylococcus aureus biofilm infection. PLoS One. 2012;7(8):e42476. doi: 10.1371/journal.pone.0042476. Epub 2012 Aug 3.
Hanke ML, Heim CE, Angle A, Sanderson SD, Kielian T. Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections. J Immunol. 2013 Mar 1;190(5):2159-68. doi: 10.4049/jimmunol.1202348. Epub 2013 Jan 30.
Neut D, Tijdens-Creusen EJ, Bulstra SK, van der Mei HC, Busscher HJ. Biofilms in chronic diabetic foot ulcers--a study of 2 cases. Acta Orthop. 2011 Jun;82(3):383-5. doi: 10.3109/17453674.2011.581265. Epub 2011 May 11. No abstract available.
Zhao G, Usui ML, Lippman SI, James GA, Stewart PS, Fleckman P, Olerud JE. Biofilms and Inflammation in Chronic Wounds. Adv Wound Care (New Rochelle). 2013 Sep;2(7):389-399. doi: 10.1089/wound.2012.0381.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1808802536
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.